SCHEMBL6357782

SCHEMBL6357782

Cc1cc(C)cc(NC(=O)Cc2ccc(OC(F)C(=O)O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NLRP3 Q96P20 3/20 0.52
▸ ALDH1A1 P00352 4/20 0.48
▸ HPGD P15428 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ SMN1; SMN2 Q16637 6/20 0.46
▸ GAA P10253 2/20 0.46
▸ RAB9A P51151 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ POLB P06746 1/20 0.44
▸ LMNA P02545 2/20 0.44
▸ NPC1 O15118 1/20 0.43
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6357275 0.86 EPHX2 (0.48) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL8700410 0.85 ALDH1A1 (0.47) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL19602224 0.84 ALDH1A1 (0.49) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL6355171 0.84 SMN1; SMN2 (0.52) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL6355594 0.82 PPARG (0.50) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL6359228 0.80 PPARG (0.47) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL8409841 0.79 SMN1; SMN2 (0.48) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL6357278 0.79 EPHX2 (0.52) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL12998282 0.78 MEN1 (0.53) NLRP3ALDH1A1HPGDKDM4EMEN1
SCHEMBL6357609 0.77 PPARA (0.48) NLRP3ALDH1A1HPGDKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154062-A1 Substituted chiral allosteric hemoglobin modifiers ALLOS THERAPEUTICS, INC. 2005-07-14 — — US disclosed
US-6894185-B2 Substituted chiral allosteric hemoglobin modifiers Allós Therapeutics, Inc. (US) 2005-05-17 — — US disclosed
EP-1206442-A4 SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS UNIV VIRGINIA COMMONWEALTH (US) 2004-12-29 — — EP disclosed
US-20030130523-A1 Substituted chiral allosteric hemoglobin modifiers ABRAHAM DONALD J (US) 2003-07-10 — — US disclosed
US-6486342-B1 Substituted chiral allosteric hemoglobin modifiers VIRGINIA COMMONWEALTH UNIVERSITY 2002-11-26 — — US disclosed
EP-1206442-A1 SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2002-05-22 — — EP disclosed
WO-2001014316-A1 SUBSTITUTED CHIRAL ALLOSTERIC HEMOGLOBIN MODIFIERS VIRGINIA COMMONWEALTH UNIVERSITY (US) 2001-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130523-A1 Substituted chiral allosteric hemoglobin modifiers HBZ, HBB, HBG2 NLRP3 4772/4885ALDH1A1 4454/4885HPGD 1583/4885
US-20050154062-A1 Substituted chiral allosteric hemoglobin modifiers HBZ, HBB, HBG2 NLRP3 4772/4885ALDH1A1 4454/4885HPGD 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback